<DOC>
	<DOCNO>NCT00003867</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness irinotecan capecitabine treat patient solid tumor respond previous treatment .</brief_summary>
	<brief_title>Irinotecan Capecitabine Treating Patients With Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose toxic effect irinotecan oral capecitabine patient gastrointestinal solid tumor . II . Characterize relationship recommend phase II dose thymidine synthase thymidine phosphorylase expression tumor response and/or toxic effect patient . OUTLINE : This dose escalation study . Patients receive oral capecitabine twice daily every twelve hour 14 day , IV irinotecan 30 minute every 3 week begin day 1 . Treatment continue least 2 course absence disease progression unacceptable toxicity . The dose capecitabine irinotecan escalate cohort 3-6 patient maximum tolerate dose ( MTD ) determine . The MTD define dose 2 6 patient experience dose limit toxicity . PROJECTED ACCRUAL : Approximately 25-30 patient accrue study .</detailed_description>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm solid tumor , include limited breast , gastrointestinal , unknown primary cancer refractory standard therapy standard therapy exist No known bone marrow involvement PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 OR WBC least 3,500/mm3 AND Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL No known Gilbert 's syndrome No significant hepatic disease require medication Renal : Creatinine great 1.5 mg/dL Cardiovascular : No significant cardiac disease require medication Other : Not pregnant nursing Fertile patient must use effective contraception No significant medical condition PRIOR CONCURRENT THERAPY : Biologic therapy : At least 2 week since prior colony stimulate factor cytokine active bone marrow Chemotherapy : At least 4 week since prior chemotherapy ( 6 week since mitomycin nitrosoureas ) No prior concurrent irinotecan fluorouracil therapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy No concurrent radiotherapy Surgery : Recovered prior major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage IV anal cancer</keyword>
	<keyword>recurrent anal cancer</keyword>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>stage IIIA anal cancer</keyword>
	<keyword>stage IIIB anal cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>regional gastrointestinal carcinoid tumor</keyword>
	<keyword>metastatic gastrointestinal carcinoid tumor</keyword>
	<keyword>recurrent gastrointestinal carcinoid tumor</keyword>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>small intestine adenocarcinoma</keyword>
	<keyword>small intestine lymphoma</keyword>
	<keyword>small intestine leiomyosarcoma</keyword>
	<keyword>unresectable gallbladder cancer</keyword>
	<keyword>recurrent gallbladder cancer</keyword>
	<keyword>unresectable extrahepatic bile duct cancer</keyword>
	<keyword>recurrent extrahepatic bile duct cancer</keyword>
	<keyword>recurrent small intestine cancer</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>newly diagnose carcinoma unknown primary</keyword>
	<keyword>carcinoma appendix</keyword>
	<keyword>recurrent carcinoma unknown primary</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>